Performance of the Abbott Real-Time PCR Assay Usingm2000spandm2000rtfor Hepatitis C Virus RNA Quantification
- 1 June 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (6) , 1726-1732
Abstract
Quantification of hepatitis C virus (HCV) RNA is essential for the everyday management of chronic hepatitis C therapy. “Real-time” PCR techniques are potentially more sensitive than classical PCR techniques, are not prone to carryover contamination, and have a consistently wider dynamic range of quantification. Thus, they are rapidly replacing other technologies for routine quantification of HCV RNA. We extensively evaluated the intrinsic characteristics and clinical performance of them2000sp-m2000rtAbbott real-time PCR platform for HCV RNA quantification. The study shows that them2000sp-m2000rtplatform is sensitive, specific, and precise; that the results are reproducible; and that the platform has a broad dynamic range of quantification. When comparing HCV RNA levels measured in the same individuals with them2000sp-m2000rtplatform and the third-generation branched-DNA assay, a trend toward a modest overestimation of HCV RNA levels was observed in them2000sp-m2000rtplatform in all genotypes except genotype 5. The differences, however, were unlikely to have any impact in clinical practice. In conclusion, our study shows that the Abbottm2000 real-time PCR system for HCV RNA quantification is sensitive, specific, and precise; that the results are reproducible; and that the platform's broad dynamic range of quantification is well suited to HCV RNA monitoring in the clinical setting.Keywords
This publication has 30 references indexed in Scilit:
- The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples #Hepatology, 2009
- The Hepatitis C Virus Life Cycle as a Target for New Antiviral TherapiesGastroenterology, 2007
- Use of Ribavirin in Patients With Chronic HCV Genotype 1: When Enough Is Really EnoughGastroenterology, 2006
- Branched DNA Technology in Molecular DiagnosticsAmerican Journal of Clinical Pathology, 2006
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis CGastroenterology, 2005
- Use and interpretation of virological tests for hepatitis CHepatology, 2002
- Performance of the New Bayer VERSANT HCV RNA 3.0 Assay for Quantitation of Hepatitis C Virus RNA in Plasma and Serum: Conversion to International Units and Comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, AssayJournal of Clinical Microbiology, 2002
- Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNAVox Sanguinis, 1999